Reported about 14 hours ago
Jefferies analysts have noted that the low uptake of COVID-19 and RSV vaccines this season aligns with market expectations but raises concerns for vaccine manufacturers. COVID-19 vaccinations have slightly increased to 2.5 million doses weekly, while RSV vaccinations have significantly dropped by 40% compared to last year. Both Moderna and Pfizer's sales forecasts are under scrutiny, with Moderna reducing its expected sales while Pfizer raises its outlook amidst ongoing uncertainties in vaccine demand post-pandemic.
Source: YAHOO